nodes	percent_of_prediction	percent_of_DWPC	metapath
Betaxolol—ADRB2—chronic obstructive pulmonary disease	0.228	0.547	CbGaD
Betaxolol—CYP1A2—chronic obstructive pulmonary disease	0.189	0.452	CbGaD
Betaxolol—ADRB2—Salbutamol—chronic obstructive pulmonary disease	0.0822	0.174	CbGbCtD
Betaxolol—ADRB1—Salbutamol—chronic obstructive pulmonary disease	0.081	0.172	CbGbCtD
Betaxolol—ADRB2—Formoterol—chronic obstructive pulmonary disease	0.0623	0.132	CbGbCtD
Betaxolol—ADRB2—Arformoterol—chronic obstructive pulmonary disease	0.0623	0.132	CbGbCtD
Betaxolol—ADRB1—Arformoterol—chronic obstructive pulmonary disease	0.0614	0.13	CbGbCtD
Betaxolol—ADRB1—Formoterol—chronic obstructive pulmonary disease	0.0614	0.13	CbGbCtD
Betaxolol—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0161	0.0342	CbGbCtD
Betaxolol—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0156	0.0331	CbGbCtD
Betaxolol—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0156	0.0331	CbGbCtD
Betaxolol—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.0139	0.0295	CbGbCtD
Betaxolol—CYP1A2—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.000631	0.0803	CbGpPWpGaD
Betaxolol—ADRB1—Adrenoceptors—ADRB2—chronic obstructive pulmonary disease	0.000448	0.057	CbGpPWpGaD
Betaxolol—Esmolol—ADRB2—chronic obstructive pulmonary disease	0.000433	0.137	CrCbGaD
Betaxolol—Atenolol—ADRB2—chronic obstructive pulmonary disease	0.000378	0.12	CrCbGaD
Betaxolol—Bisoprolol—ADRB2—chronic obstructive pulmonary disease	0.000368	0.117	CrCbGaD
Betaxolol—Acebutolol—ADRB2—chronic obstructive pulmonary disease	0.000348	0.11	CrCbGaD
Betaxolol—Oxprenolol—ADRB2—chronic obstructive pulmonary disease	0.000346	0.11	CrCbGaD
Betaxolol—Alprenolol—ADRB2—chronic obstructive pulmonary disease	0.000316	0.1	CrCbGaD
Betaxolol—Metoprolol—ADRB2—chronic obstructive pulmonary disease	0.000294	0.0933	CrCbGaD
Betaxolol—Pindolol—ADRB2—chronic obstructive pulmonary disease	0.000272	0.0863	CrCbGaD
Betaxolol—ADRB1—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000202	0.0258	CbGpPWpGaD
Betaxolol—CYP1A2—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000201	0.0255	CbGpPWpGaD
Betaxolol—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000171	0.0218	CbGpPWpGaD
Betaxolol—CYP2D6—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.00016	0.0203	CbGpPWpGaD
Betaxolol—ADRB1—Monoamine GPCRs—ADRB2—chronic obstructive pulmonary disease	0.000158	0.0202	CbGpPWpGaD
Betaxolol—ADRB1—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000157	0.02	CbGpPWpGaD
Betaxolol—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000156	0.0198	CbGpPWpGaD
Betaxolol—Propranolol—ADRB2—chronic obstructive pulmonary disease	0.000148	0.0471	CrCbGaD
Betaxolol—ADRB1—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000147	0.0187	CbGpPWpGaD
Betaxolol—ADRB1—Endothelin Pathways—EDN1—chronic obstructive pulmonary disease	0.000142	0.018	CbGpPWpGaD
Betaxolol—CYP2D6—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000134	0.017	CbGpPWpGaD
Betaxolol—ADRB1—Amine ligand-binding receptors—ADRB2—chronic obstructive pulmonary disease	0.000133	0.0169	CbGpPWpGaD
Betaxolol—CYP2D6—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000128	0.0163	CbGpPWpGaD
Betaxolol—Propranolol—CYP1A1—chronic obstructive pulmonary disease	0.000127	0.0404	CrCbGaD
Betaxolol—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000126	0.00127	CcSEcCtD
Betaxolol—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000126	0.00127	CcSEcCtD
Betaxolol—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000125	0.00126	CcSEcCtD
Betaxolol—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000125	0.00125	CcSEcCtD
Betaxolol—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000125	0.00125	CcSEcCtD
Betaxolol—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000125	0.00125	CcSEcCtD
Betaxolol—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000125	0.00125	CcSEcCtD
Betaxolol—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000125	0.00125	CcSEcCtD
Betaxolol—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000125	0.00125	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Montelukast—chronic obstructive pulmonary disease	0.000124	0.00125	CcSEcCtD
Betaxolol—ADRB1—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000124	0.0158	CbGpPWpGaD
Betaxolol—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000124	0.00124	CcSEcCtD
Betaxolol—Propranolol—CYP1A2—chronic obstructive pulmonary disease	0.000123	0.0389	CrCbGaD
Betaxolol—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000123	0.00123	CcSEcCtD
Betaxolol—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000123	0.00123	CcSEcCtD
Betaxolol—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000122	0.00122	CcSEcCtD
Betaxolol—Infection—Formoterol—chronic obstructive pulmonary disease	0.000122	0.00122	CcSEcCtD
Betaxolol—ADRB2—Monoamine GPCRs—HTR2A—chronic obstructive pulmonary disease	0.000121	0.0154	CbGpPWpGaD
Betaxolol—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.00121	CcSEcCtD
Betaxolol—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.00121	CcSEcCtD
Betaxolol—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000121	0.00121	CcSEcCtD
Betaxolol—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000121	0.00121	CcSEcCtD
Betaxolol—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.00012	0.00121	CcSEcCtD
Betaxolol—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.00012	0.0012	CcSEcCtD
Betaxolol—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.00012	0.0012	CcSEcCtD
Betaxolol—Oedema—Montelukast—chronic obstructive pulmonary disease	0.00012	0.0012	CcSEcCtD
Betaxolol—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.00012	0.0012	CcSEcCtD
Betaxolol—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.00012	0.0012	CcSEcCtD
Betaxolol—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000119	0.00119	CcSEcCtD
Betaxolol—Infection—Montelukast—chronic obstructive pulmonary disease	0.000119	0.00119	CcSEcCtD
Betaxolol—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000119	0.00119	CcSEcCtD
Betaxolol—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000119	0.00119	CcSEcCtD
Betaxolol—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000119	0.00119	CcSEcCtD
Betaxolol—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000118	0.00118	CcSEcCtD
Betaxolol—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000118	0.00118	CcSEcCtD
Betaxolol—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000118	0.00118	CcSEcCtD
Betaxolol—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000117	0.00117	CcSEcCtD
Betaxolol—CYP1A2—Estrogen Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000116	0.0148	CbGpPWpGaD
Betaxolol—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000116	0.0148	CbGpPWpGaD
Betaxolol—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000116	0.00116	CcSEcCtD
Betaxolol—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000115	0.00115	CcSEcCtD
Betaxolol—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000115	0.00115	CcSEcCtD
Betaxolol—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000115	0.00115	CcSEcCtD
Betaxolol—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000114	0.00114	CcSEcCtD
Betaxolol—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000114	0.00114	CcSEcCtD
Betaxolol—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000114	0.00114	CcSEcCtD
Betaxolol—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000113	0.00114	CcSEcCtD
Betaxolol—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000113	0.00113	CcSEcCtD
Betaxolol—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.000113	0.00113	CcSEcCtD
Betaxolol—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000112	0.00113	CcSEcCtD
Betaxolol—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000112	0.00112	CcSEcCtD
Betaxolol—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000112	0.00112	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000112	0.00112	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000112	0.00112	CcSEcCtD
Betaxolol—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.000111	0.00111	CcSEcCtD
Betaxolol—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.000111	0.00111	CcSEcCtD
Betaxolol—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.00011	0.00111	CcSEcCtD
Betaxolol—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00011	0.0011	CcSEcCtD
Betaxolol—ADRB2—GPCRs, Other—CXCR2—chronic obstructive pulmonary disease	0.00011	0.014	CbGpPWpGaD
Betaxolol—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.00011	0.0011	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000109	0.0011	CcSEcCtD
Betaxolol—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000109	0.00109	CcSEcCtD
Betaxolol—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000109	0.00109	CcSEcCtD
Betaxolol—ADRB1—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	0.000109	0.0138	CbGpPWpGaD
Betaxolol—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000109	0.00109	CcSEcCtD
Betaxolol—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000108	0.00108	CcSEcCtD
Betaxolol—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000108	0.00108	CcSEcCtD
Betaxolol—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000108	0.00108	CcSEcCtD
Betaxolol—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000108	0.00108	CcSEcCtD
Betaxolol—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000107	0.00108	CcSEcCtD
Betaxolol—Injury—Prednisone—chronic obstructive pulmonary disease	0.000107	0.00107	CcSEcCtD
Betaxolol—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000107	0.00107	CcSEcCtD
Betaxolol—ADRB2—G alpha (s) signalling events—PDE4A—chronic obstructive pulmonary disease	0.000106	0.0135	CbGpPWpGaD
Betaxolol—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.00106	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000106	0.00106	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000106	0.00106	CcSEcCtD
Betaxolol—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000106	0.00106	CcSEcCtD
Betaxolol—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000106	0.00106	CcSEcCtD
Betaxolol—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000106	0.00106	CcSEcCtD
Betaxolol—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000105	0.00106	CcSEcCtD
Betaxolol—Pain—Formoterol—chronic obstructive pulmonary disease	0.000105	0.00105	CcSEcCtD
Betaxolol—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000105	0.00105	CcSEcCtD
Betaxolol—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000105	0.00105	CcSEcCtD
Betaxolol—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000105	0.00105	CcSEcCtD
Betaxolol—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000105	0.00105	CcSEcCtD
Betaxolol—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000104	0.00105	CcSEcCtD
Betaxolol—Amnesia—Prednisone—chronic obstructive pulmonary disease	0.000104	0.00105	CcSEcCtD
Betaxolol—ADRB1—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000104	0.0132	CbGpPWpGaD
Betaxolol—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000104	0.00104	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000104	0.00104	CcSEcCtD
Betaxolol—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000104	0.00104	CcSEcCtD
Betaxolol—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000103	0.00103	CcSEcCtD
Betaxolol—Pain—Montelukast—chronic obstructive pulmonary disease	0.000103	0.00103	CcSEcCtD
Betaxolol—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000103	0.00103	CcSEcCtD
Betaxolol—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000102	0.00103	CcSEcCtD
Betaxolol—Neuropathy peripheral—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.00102	CcSEcCtD
Betaxolol—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.000102	0.00102	CcSEcCtD
Betaxolol—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000102	0.00102	CcSEcCtD
Betaxolol—ADRB2—Amine ligand-binding receptors—HTR2A—chronic obstructive pulmonary disease	0.000102	0.013	CbGpPWpGaD
Betaxolol—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000102	0.00102	CcSEcCtD
Betaxolol—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000102	0.00102	CcSEcCtD
Betaxolol—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000101	0.00102	CcSEcCtD
Betaxolol—Conjunctivitis—Prednisolone—chronic obstructive pulmonary disease	0.000101	0.00101	CcSEcCtD
Betaxolol—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000101	0.00101	CcSEcCtD
Betaxolol—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000101	0.00101	CcSEcCtD
Betaxolol—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000101	0.00101	CcSEcCtD
Betaxolol—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000101	0.00101	CcSEcCtD
Betaxolol—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000101	0.00101	CcSEcCtD
Betaxolol—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.0001	0.00101	CcSEcCtD
Betaxolol—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.0001	0.001	CcSEcCtD
Betaxolol—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	9.99e-05	0.001	CcSEcCtD
Betaxolol—Fatigue—Salbutamol—chronic obstructive pulmonary disease	9.98e-05	0.000999	CcSEcCtD
Betaxolol—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	9.92e-05	0.0126	CbGpPWpGaD
Betaxolol—Pain—Salbutamol—chronic obstructive pulmonary disease	9.9e-05	0.000991	CcSEcCtD
Betaxolol—Constipation—Salbutamol—chronic obstructive pulmonary disease	9.9e-05	0.000991	CcSEcCtD
Betaxolol—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	9.83e-05	0.0125	CbGpPWpGaD
Betaxolol—Osteoarthritis—Prednisone—chronic obstructive pulmonary disease	9.82e-05	0.000983	CcSEcCtD
Betaxolol—Urticaria—Formoterol—chronic obstructive pulmonary disease	9.74e-05	0.000975	CcSEcCtD
Betaxolol—Urticaria—Arformoterol—chronic obstructive pulmonary disease	9.74e-05	0.000975	CcSEcCtD
Betaxolol—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	9.7e-05	0.0123	CbGpPWpGaD
Betaxolol—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	9.69e-05	0.000971	CcSEcCtD
Betaxolol—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	9.69e-05	0.000971	CcSEcCtD
Betaxolol—Affect lability—Prednisone—chronic obstructive pulmonary disease	9.66e-05	0.000968	CcSEcCtD
Betaxolol—Vomiting—Tiotropium—chronic obstructive pulmonary disease	9.66e-05	0.000967	CcSEcCtD
Betaxolol—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	9.59e-05	0.00096	CcSEcCtD
Betaxolol—Rash—Tiotropium—chronic obstructive pulmonary disease	9.58e-05	0.000959	CcSEcCtD
Betaxolol—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	9.57e-05	0.000958	CcSEcCtD
Betaxolol—Nausea—Aminophylline—chronic obstructive pulmonary disease	9.57e-05	0.000958	CcSEcCtD
Betaxolol—Urticaria—Montelukast—chronic obstructive pulmonary disease	9.54e-05	0.000955	CcSEcCtD
Betaxolol—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	9.54e-05	0.000955	CcSEcCtD
Betaxolol—Headache—Tiotropium—chronic obstructive pulmonary disease	9.52e-05	0.000953	CcSEcCtD
Betaxolol—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	9.51e-05	0.000953	CcSEcCtD
Betaxolol—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	9.49e-05	0.000951	CcSEcCtD
Betaxolol—CYP1A2—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	9.43e-05	0.012	CbGpPWpGaD
Betaxolol—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	9.33e-05	0.0119	CbGpPWpGaD
Betaxolol—Mood swings—Prednisone—chronic obstructive pulmonary disease	9.3e-05	0.000931	CcSEcCtD
Betaxolol—Urticaria—Salbutamol—chronic obstructive pulmonary disease	9.2e-05	0.000921	CcSEcCtD
Betaxolol—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	9.15e-05	0.000916	CcSEcCtD
Betaxolol—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	9.03e-05	0.000905	CcSEcCtD
Betaxolol—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	9.03e-05	0.000905	CcSEcCtD
Betaxolol—Nausea—Tiotropium—chronic obstructive pulmonary disease	9.02e-05	0.000904	CcSEcCtD
Betaxolol—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	9e-05	0.000902	CcSEcCtD
Betaxolol—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	8.94e-05	0.0114	CbGpPWpGaD
Betaxolol—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	8.93e-05	0.000895	CcSEcCtD
Betaxolol—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	8.85e-05	0.000886	CcSEcCtD
Betaxolol—Asthenia—Arformoterol—chronic obstructive pulmonary disease	8.79e-05	0.000881	CcSEcCtD
Betaxolol—Asthenia—Formoterol—chronic obstructive pulmonary disease	8.79e-05	0.000881	CcSEcCtD
Betaxolol—Pruritus—Formoterol—chronic obstructive pulmonary disease	8.67e-05	0.000869	CcSEcCtD
Betaxolol—Pruritus—Arformoterol—chronic obstructive pulmonary disease	8.67e-05	0.000869	CcSEcCtD
Betaxolol—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	8.66e-05	0.000867	CcSEcCtD
Betaxolol—ADRB1—Endothelin Pathways—NOS3—chronic obstructive pulmonary disease	8.63e-05	0.011	CbGpPWpGaD
Betaxolol—Asthenia—Montelukast—chronic obstructive pulmonary disease	8.61e-05	0.000863	CcSEcCtD
Betaxolol—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	8.53e-05	0.000854	CcSEcCtD
Betaxolol—Pruritus—Montelukast—chronic obstructive pulmonary disease	8.49e-05	0.000851	CcSEcCtD
Betaxolol—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	8.39e-05	0.00084	CcSEcCtD
Betaxolol—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	8.39e-05	0.00084	CcSEcCtD
Betaxolol—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	8.35e-05	0.000836	CcSEcCtD
Betaxolol—Asthenia—Salbutamol—chronic obstructive pulmonary disease	8.3e-05	0.000832	CcSEcCtD
Betaxolol—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	8.22e-05	0.0105	CbGpPWpGaD
Betaxolol—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	8.22e-05	0.000823	CcSEcCtD
Betaxolol—Pruritus—Salbutamol—chronic obstructive pulmonary disease	8.19e-05	0.00082	CcSEcCtD
Betaxolol—Erythema—Prednisolone—chronic obstructive pulmonary disease	8.13e-05	0.000815	CcSEcCtD
Betaxolol—Dizziness—Arformoterol—chronic obstructive pulmonary disease	8.11e-05	0.000812	CcSEcCtD
Betaxolol—Dizziness—Formoterol—chronic obstructive pulmonary disease	8.11e-05	0.000812	CcSEcCtD
Betaxolol—Dizziness—Montelukast—chronic obstructive pulmonary disease	7.94e-05	0.000795	CcSEcCtD
Betaxolol—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	7.92e-05	0.000793	CcSEcCtD
Betaxolol—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	7.9e-05	0.0101	CbGpPWpGaD
Betaxolol—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	7.81e-05	0.000783	CcSEcCtD
Betaxolol—Vomiting—Formoterol—chronic obstructive pulmonary disease	7.79e-05	0.000781	CcSEcCtD
Betaxolol—Vomiting—Arformoterol—chronic obstructive pulmonary disease	7.79e-05	0.000781	CcSEcCtD
Betaxolol—Rash—Formoterol—chronic obstructive pulmonary disease	7.73e-05	0.000774	CcSEcCtD
Betaxolol—Rash—Arformoterol—chronic obstructive pulmonary disease	7.73e-05	0.000774	CcSEcCtD
Betaxolol—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	7.72e-05	0.000773	CcSEcCtD
Betaxolol—Dermatitis—Formoterol—chronic obstructive pulmonary disease	7.72e-05	0.000773	CcSEcCtD
Betaxolol—Weight increased—Prednisone—chronic obstructive pulmonary disease	7.72e-05	0.000773	CcSEcCtD
Betaxolol—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	7.69e-05	0.00978	CbGpPWpGaD
Betaxolol—Headache—Arformoterol—chronic obstructive pulmonary disease	7.68e-05	0.000769	CcSEcCtD
Betaxolol—Headache—Formoterol—chronic obstructive pulmonary disease	7.68e-05	0.000769	CcSEcCtD
Betaxolol—Weight decreased—Prednisone—chronic obstructive pulmonary disease	7.67e-05	0.000769	CcSEcCtD
Betaxolol—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	7.67e-05	0.000768	CcSEcCtD
Betaxolol—Dizziness—Salbutamol—chronic obstructive pulmonary disease	7.65e-05	0.000767	CcSEcCtD
Betaxolol—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	7.65e-05	0.000766	CcSEcCtD
Betaxolol—Vomiting—Montelukast—chronic obstructive pulmonary disease	7.63e-05	0.000765	CcSEcCtD
Betaxolol—Rash—Montelukast—chronic obstructive pulmonary disease	7.57e-05	0.000758	CcSEcCtD
Betaxolol—Dermatitis—Montelukast—chronic obstructive pulmonary disease	7.56e-05	0.000758	CcSEcCtD
Betaxolol—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	7.55e-05	0.000756	CcSEcCtD
Betaxolol—Depression—Prednisone—chronic obstructive pulmonary disease	7.54e-05	0.000755	CcSEcCtD
Betaxolol—Headache—Montelukast—chronic obstructive pulmonary disease	7.52e-05	0.000753	CcSEcCtD
Betaxolol—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	7.46e-05	0.000747	CcSEcCtD
Betaxolol—Neuropathy peripheral—Prednisone—chronic obstructive pulmonary disease	7.41e-05	0.000743	CcSEcCtD
Betaxolol—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	7.41e-05	0.000743	CcSEcCtD
Betaxolol—Vomiting—Salbutamol—chronic obstructive pulmonary disease	7.36e-05	0.000737	CcSEcCtD
Betaxolol—Malaise—Prednisolone—chronic obstructive pulmonary disease	7.34e-05	0.000735	CcSEcCtD
Betaxolol—Vertigo—Prednisolone—chronic obstructive pulmonary disease	7.31e-05	0.000732	CcSEcCtD
Betaxolol—Rash—Salbutamol—chronic obstructive pulmonary disease	7.3e-05	0.000731	CcSEcCtD
Betaxolol—Syncope—Prednisolone—chronic obstructive pulmonary disease	7.29e-05	0.000731	CcSEcCtD
Betaxolol—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	7.29e-05	0.00073	CcSEcCtD
Betaxolol—Nausea—Arformoterol—chronic obstructive pulmonary disease	7.28e-05	0.000729	CcSEcCtD
Betaxolol—Nausea—Formoterol—chronic obstructive pulmonary disease	7.28e-05	0.000729	CcSEcCtD
Betaxolol—Headache—Salbutamol—chronic obstructive pulmonary disease	7.25e-05	0.000726	CcSEcCtD
Betaxolol—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	7.21e-05	0.00917	CbGpPWpGaD
Betaxolol—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	7.15e-05	0.000716	CcSEcCtD
Betaxolol—Nausea—Montelukast—chronic obstructive pulmonary disease	7.13e-05	0.000714	CcSEcCtD
Betaxolol—Bradycardia—Prednisone—chronic obstructive pulmonary disease	6.91e-05	0.000692	CcSEcCtD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	6.91e-05	0.00879	CbGpPWpGaD
Betaxolol—Nausea—Salbutamol—chronic obstructive pulmonary disease	6.88e-05	0.000689	CcSEcCtD
Betaxolol—Discomfort—Prednisolone—chronic obstructive pulmonary disease	6.84e-05	0.000685	CcSEcCtD
Betaxolol—Hallucination—Prednisone—chronic obstructive pulmonary disease	6.76e-05	0.000677	CcSEcCtD
Betaxolol—Oedema—Prednisolone—chronic obstructive pulmonary disease	6.64e-05	0.000665	CcSEcCtD
Betaxolol—Shock—Prednisolone—chronic obstructive pulmonary disease	6.53e-05	0.000654	CcSEcCtD
Betaxolol—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	6.52e-05	0.00829	CbGpPWpGaD
Betaxolol—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	6.48e-05	0.000649	CcSEcCtD
Betaxolol—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	6.42e-05	0.000643	CcSEcCtD
Betaxolol—Eye disorder—Prednisone—chronic obstructive pulmonary disease	6.35e-05	0.000636	CcSEcCtD
Betaxolol—Flushing—Prednisone—chronic obstructive pulmonary disease	6.3e-05	0.000631	CcSEcCtD
Betaxolol—Angiopathy—Prednisone—chronic obstructive pulmonary disease	6.16e-05	0.000617	CcSEcCtD
Betaxolol—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	6.13e-05	0.000614	CcSEcCtD
Betaxolol—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	6.11e-05	0.00777	CbGpPWpGaD
Betaxolol—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	6.07e-05	0.000608	CcSEcCtD
Betaxolol—Insomnia—Prednisolone—chronic obstructive pulmonary disease	6e-05	0.000601	CcSEcCtD
Betaxolol—Alopecia—Prednisone—chronic obstructive pulmonary disease	6e-05	0.000601	CcSEcCtD
Betaxolol—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	5.96e-05	0.000597	CcSEcCtD
Betaxolol—Mental disorder—Prednisone—chronic obstructive pulmonary disease	5.95e-05	0.000596	CcSEcCtD
Betaxolol—Erythema—Prednisone—chronic obstructive pulmonary disease	5.91e-05	0.000592	CcSEcCtD
Betaxolol—Malnutrition—Prednisone—chronic obstructive pulmonary disease	5.91e-05	0.000592	CcSEcCtD
Betaxolol—Pain—Prednisolone—chronic obstructive pulmonary disease	5.68e-05	0.000569	CcSEcCtD
Betaxolol—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	5.67e-05	0.00721	CbGpPWpGaD
Betaxolol—Vision blurred—Prednisone—chronic obstructive pulmonary disease	5.57e-05	0.000558	CcSEcCtD
Betaxolol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	5.54e-05	0.00705	CbGpPWpGaD
Betaxolol—ADRB1—G alpha (s) signalling events—ADRB2—chronic obstructive pulmonary disease	5.49e-05	0.00699	CbGpPWpGaD
Betaxolol—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	5.48e-05	0.000549	CcSEcCtD
Betaxolol—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	5.47e-05	0.00696	CbGpPWpGaD
Betaxolol—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	5.47e-05	0.000548	CcSEcCtD
Betaxolol—Anaemia—Prednisone—chronic obstructive pulmonary disease	5.46e-05	0.000547	CcSEcCtD
Betaxolol—ADRB2—GPCRs, Other—HTR2A—chronic obstructive pulmonary disease	5.38e-05	0.00685	CbGpPWpGaD
Betaxolol—Malaise—Prednisone—chronic obstructive pulmonary disease	5.33e-05	0.000534	CcSEcCtD
Betaxolol—Vertigo—Prednisone—chronic obstructive pulmonary disease	5.31e-05	0.000532	CcSEcCtD
Betaxolol—Syncope—Prednisone—chronic obstructive pulmonary disease	5.3e-05	0.000531	CcSEcCtD
Betaxolol—Urticaria—Prednisolone—chronic obstructive pulmonary disease	5.27e-05	0.000528	CcSEcCtD
Betaxolol—ADRB2—Arf6 signaling events—EGFR—chronic obstructive pulmonary disease	5.22e-05	0.00664	CbGpPWpGaD
Betaxolol—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	5.2e-05	0.00052	CcSEcCtD
Betaxolol—Myalgia—Prednisone—chronic obstructive pulmonary disease	5.03e-05	0.000504	CcSEcCtD
Betaxolol—Arthralgia—Prednisone—chronic obstructive pulmonary disease	5.03e-05	0.000504	CcSEcCtD
Betaxolol—Anxiety—Prednisone—chronic obstructive pulmonary disease	5.01e-05	0.000502	CcSEcCtD
Betaxolol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—chronic obstructive pulmonary disease	5e-05	0.000501	CcSEcCtD
Betaxolol—Discomfort—Prednisone—chronic obstructive pulmonary disease	4.97e-05	0.000498	CcSEcCtD
Betaxolol—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	4.89e-05	0.00049	CcSEcCtD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	4.87e-05	0.0062	CbGpPWpGaD
Betaxolol—Oedema—Prednisone—chronic obstructive pulmonary disease	4.82e-05	0.000483	CcSEcCtD
Betaxolol—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	4.8e-05	0.00611	CbGpPWpGaD
Betaxolol—Infection—Prednisone—chronic obstructive pulmonary disease	4.79e-05	0.00048	CcSEcCtD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—CXCR2—chronic obstructive pulmonary disease	4.77e-05	0.00607	CbGpPWpGaD
Betaxolol—Shock—Prednisone—chronic obstructive pulmonary disease	4.75e-05	0.000475	CcSEcCtD
Betaxolol—ADRB1—Calcium Regulation in the Cardiac Cell—ADRB2—chronic obstructive pulmonary disease	4.74e-05	0.00603	CbGpPWpGaD
Betaxolol—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	4.73e-05	0.000474	CcSEcCtD
Betaxolol—Tachycardia—Prednisone—chronic obstructive pulmonary disease	4.71e-05	0.000472	CcSEcCtD
Betaxolol—Skin disorder—Prednisone—chronic obstructive pulmonary disease	4.69e-05	0.000469	CcSEcCtD
Betaxolol—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	4.66e-05	0.000467	CcSEcCtD
Betaxolol—Anorexia—Prednisone—chronic obstructive pulmonary disease	4.6e-05	0.000461	CcSEcCtD
Betaxolol—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	4.5e-05	0.00572	CbGpPWpGaD
Betaxolol—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	4.4e-05	0.00044	CcSEcCtD
Betaxolol—Dizziness—Prednisolone—chronic obstructive pulmonary disease	4.39e-05	0.00044	CcSEcCtD
Betaxolol—Insomnia—Prednisone—chronic obstructive pulmonary disease	4.36e-05	0.000437	CcSEcCtD
Betaxolol—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	4.33e-05	0.000434	CcSEcCtD
Betaxolol—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	4.25e-05	0.000425	CcSEcCtD
Betaxolol—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	4.22e-05	0.00537	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	4.22e-05	0.00537	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	4.22e-05	0.00537	CbGpPWpGaD
Betaxolol—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	4.19e-05	0.00042	CcSEcCtD
Betaxolol—Rash—Prednisolone—chronic obstructive pulmonary disease	4.19e-05	0.000419	CcSEcCtD
Betaxolol—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	4.18e-05	0.000419	CcSEcCtD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	4.18e-05	0.00531	CbGpPWpGaD
Betaxolol—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	4.16e-05	0.00529	CbGpPWpGaD
Betaxolol—Fatigue—Prednisone—chronic obstructive pulmonary disease	4.16e-05	0.000417	CcSEcCtD
Betaxolol—Headache—Prednisolone—chronic obstructive pulmonary disease	4.16e-05	0.000417	CcSEcCtD
Betaxolol—Constipation—Prednisone—chronic obstructive pulmonary disease	4.13e-05	0.000413	CcSEcCtD
Betaxolol—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	4.11e-05	0.00523	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCR2—chronic obstructive pulmonary disease	4.09e-05	0.0052	CbGpPWpGaD
Betaxolol—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	4.03e-05	0.00512	CbGpPWpGaD
Betaxolol—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	3.98e-05	0.00506	CbGpPWpGaD
Betaxolol—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	3.98e-05	0.000398	CcSEcCtD
Betaxolol—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	3.95e-05	0.00502	CbGpPWpGaD
Betaxolol—Nausea—Prednisolone—chronic obstructive pulmonary disease	3.94e-05	0.000395	CcSEcCtD
Betaxolol—Urticaria—Prednisone—chronic obstructive pulmonary disease	3.83e-05	0.000384	CcSEcCtD
Betaxolol—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	3.81e-05	0.000382	CcSEcCtD
Betaxolol—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	3.55e-05	0.000356	CcSEcCtD
Betaxolol—Asthenia—Prednisone—chronic obstructive pulmonary disease	3.46e-05	0.000347	CcSEcCtD
Betaxolol—Pruritus—Prednisone—chronic obstructive pulmonary disease	3.41e-05	0.000342	CcSEcCtD
Betaxolol—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	3.41e-05	0.00434	CbGpPWpGaD
Betaxolol—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	3.37e-05	0.00428	CbGpPWpGaD
Betaxolol—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	3.3e-05	0.000331	CcSEcCtD
Betaxolol—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	3.27e-05	0.00415	CbGpPWpGaD
Betaxolol—Dizziness—Prednisone—chronic obstructive pulmonary disease	3.19e-05	0.00032	CcSEcCtD
Betaxolol—ADRB1—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	3.18e-05	0.00405	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	3.11e-05	0.00396	CbGpPWpGaD
Betaxolol—Vomiting—Prednisone—chronic obstructive pulmonary disease	3.07e-05	0.000307	CcSEcCtD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	3.06e-05	0.00389	CbGpPWpGaD
Betaxolol—Rash—Prednisone—chronic obstructive pulmonary disease	3.04e-05	0.000305	CcSEcCtD
Betaxolol—Dermatitis—Prednisone—chronic obstructive pulmonary disease	3.04e-05	0.000304	CcSEcCtD
Betaxolol—Headache—Prednisone—chronic obstructive pulmonary disease	3.02e-05	0.000303	CcSEcCtD
Betaxolol—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	2.88e-05	0.00367	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	2.87e-05	0.00365	CbGpPWpGaD
Betaxolol—Nausea—Prednisone—chronic obstructive pulmonary disease	2.87e-05	0.000287	CcSEcCtD
Betaxolol—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	2.84e-05	0.00361	CbGpPWpGaD
Betaxolol—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	2.77e-05	0.00352	CbGpPWpGaD
Betaxolol—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	2.65e-05	0.00337	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	2.62e-05	0.00333	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	2.6e-05	0.00331	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	2.55e-05	0.00324	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	2.43e-05	0.0031	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	2.41e-05	0.00306	CbGpPWpGaD
Betaxolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	2.39e-05	0.00304	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	2.39e-05	0.00304	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	2.35e-05	0.003	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	2.34e-05	0.00298	CbGpPWpGaD
Betaxolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	2.34e-05	0.00297	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	2.34e-05	0.00297	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	2.29e-05	0.00291	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	2.23e-05	0.00284	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	2.18e-05	0.00277	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	2.05e-05	0.00261	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	2.02e-05	0.00258	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	2e-05	0.00255	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	1.99e-05	0.00254	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.99e-05	0.00253	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	1.98e-05	0.00252	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	1.98e-05	0.00252	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.96e-05	0.0025	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.83e-05	0.00233	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	1.81e-05	0.00231	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.8e-05	0.0023	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	1.8e-05	0.00229	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	1.78e-05	0.00227	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	1.78e-05	0.00226	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	1.78e-05	0.00226	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	1.76e-05	0.00224	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	1.74e-05	0.00222	CbGpPWpGaD
Betaxolol—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.73e-05	0.00221	CbGpPWpGaD
Betaxolol—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.71e-05	0.00218	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	1.71e-05	0.00218	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	1.69e-05	0.00216	CbGpPWpGaD
Betaxolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	1.69e-05	0.00216	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	1.69e-05	0.00215	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	1.66e-05	0.00212	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	1.63e-05	0.00208	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	1.6e-05	0.00203	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	1.58e-05	0.00201	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	1.56e-05	0.00198	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	1.55e-05	0.00197	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	1.54e-05	0.00196	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	1.53e-05	0.00195	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	1.53e-05	0.00194	CbGpPWpGaD
Betaxolol—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	1.47e-05	0.00187	CbGpPWpGaD
Betaxolol—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.45e-05	0.00184	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	1.4e-05	0.00178	CbGpPWpGaD
Betaxolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.27e-05	0.00161	CbGpPWpGaD
Betaxolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.24e-05	0.00157	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.2e-05	0.00152	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	1.18e-05	0.0015	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.17e-05	0.00149	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.13e-05	0.00143	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.02e-05	0.0013	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.01e-05	0.00128	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	9.85e-06	0.00125	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	9.64e-06	0.00123	CbGpPWpGaD
Betaxolol—ADRB1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	9.63e-06	0.00123	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	9.43e-06	0.0012	CbGpPWpGaD
Betaxolol—ADRB2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	9.42e-06	0.0012	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	9.25e-06	0.00118	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	9.15e-06	0.00116	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	8.99e-06	0.00114	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	8.95e-06	0.00114	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	8.81e-06	0.00112	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	8.62e-06	0.0011	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	8.43e-06	0.00107	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	8.36e-06	0.00106	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	8e-06	0.00102	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	7.83e-06	0.000996	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	7.83e-06	0.000996	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	7.62e-06	0.000969	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	7.08e-06	0.000901	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	7.05e-06	0.000897	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	6.9e-06	0.000877	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—KL—chronic obstructive pulmonary disease	6.55e-06	0.000834	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—KL—chronic obstructive pulmonary disease	6.41e-06	0.000815	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	6.05e-06	0.000769	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	5.64e-06	0.000718	CbGpPWpGaD
Betaxolol—ADRB1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	5.44e-06	0.000693	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	5.4e-06	0.000687	CbGpPWpGaD
Betaxolol—ADRB2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	5.33e-06	0.000678	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	5.29e-06	0.000672	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.94e-06	0.000629	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.91e-06	0.000625	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.91e-06	0.000625	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	4.86e-06	0.000618	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	4.84e-06	0.000615	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	4.81e-06	0.000611	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.73e-06	0.000601	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.62e-06	0.000588	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	4.43e-06	0.000564	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.4e-06	0.000559	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.3e-06	0.000547	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	4.16e-06	0.000529	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	4.11e-06	0.000523	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	4.08e-06	0.000519	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	3.84e-06	0.000488	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	3.75e-06	0.000478	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.61e-06	0.00046	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.54e-06	0.00045	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.45e-06	0.000439	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.41e-06	0.000433	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.37e-06	0.000429	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.36e-06	0.000427	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.29e-06	0.000419	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.22e-06	0.00041	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.13e-06	0.000398	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.97e-06	0.000377	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.92e-06	0.000372	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.89e-06	0.000367	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	2.86e-06	0.000363	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.85e-06	0.000362	CbGpPWpGaD
Betaxolol—ADRB1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.78e-06	0.000353	CbGpPWpGaD
Betaxolol—ADRB2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.72e-06	0.000346	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.65e-06	0.000337	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.64e-06	0.000336	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.58e-06	0.000329	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.51e-06	0.00032	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.37e-06	0.000302	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.32e-06	0.000295	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.18e-06	0.000277	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.13e-06	0.000272	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.13e-06	0.000271	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.09e-06	0.000266	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	2.02e-06	0.000257	CbGpPWpGaD
Betaxolol—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	1.93e-06	0.000245	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.79e-06	0.000228	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.75e-06	0.000223	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	1.71e-06	0.000217	CbGpPWpGaD
Betaxolol—ADRB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.64e-06	0.000209	CbGpPWpGaD
Betaxolol—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	1.63e-06	0.000208	CbGpPWpGaD
Betaxolol—ADRB2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.6e-06	0.000204	CbGpPWpGaD
